OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
Daniele Focosi
Viruses (2023) Vol. 15, Iss. 5, pp. 1048-1048
Open Access | Times Cited: 9
Daniele Focosi
Viruses (2023) Vol. 15, Iss. 5, pp. 1048-1048
Open Access | Times Cited: 9
Showing 9 citing articles:
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 31
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 31
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Subsequent Waves of Convergent Evolution in SARS-CoV-2 Genes and Proteins
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2024) Vol. 12, Iss. 8, pp. 887-887
Open Access | Times Cited: 5
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2024) Vol. 12, Iss. 8, pp. 887-887
Open Access | Times Cited: 5
Sipavibart: when a success changes into a failure
Daniele Focosi, Arturo Casadevall
The Lancet Infectious Diseases (2025)
Closed Access
Daniele Focosi, Arturo Casadevall
The Lancet Infectious Diseases (2025)
Closed Access
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2023) Vol. 11, Iss. 11, pp. 1634-1634
Open Access | Times Cited: 13
Daniele Focosi, Pietro Giorgio Spezia, Fabrizio Maggi
Vaccines (2023) Vol. 11, Iss. 11, pp. 1634-1634
Open Access | Times Cited: 13
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
